ICD-10 Code C81.27 | Mixed cellularity Hodgkin lymphoma, spleen Symptoms, Diagnosis, Billing

Mixed cellularity Hodgkin lymphoma, spleen is a subtype of Hodgkin lymphoma characterized by a heterogeneous mixture of cell types, including Reed-Sternberg cells. This condition primarily affects the spleen and is significant due to its potential for systemic involvement and progression. Accurate coding with ICD-10 Code C81.27 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that patients receive appropriate care and resources.

What is ICD-10 Code C81.27 for Mixed cellularity Hodgkin lymphoma, spleen?

ICD-10 Code C81.27 specifically denotes Mixed cellularity Hodgkin lymphoma affecting the spleen. This code is utilized when documenting cases where the disease presents with a mixture of cellular components, indicating a more complex pathology. It should be applied in clinical documentation and billing when the diagnosis is confirmed through histological examination and when the spleen is involved.

ICD-10 Code C81.27 – Clinical Definition and Explanation of Mixed cellularity Hodgkin lymphoma, spleen

Mixed cellularity Hodgkin lymphoma, spleen is caused by the proliferation of atypical lymphoid cells, including Reed-Sternberg cells, leading to splenic enlargement and potential systemic symptoms. This condition requires prompt medical attention due to its aggressive nature and risk of progression to more advanced stages of lymphoma.

Key Clinical Features:

• Splenomegaly (enlarged spleen) often detected during physical examination.
• Presence of Reed-Sternberg cells in biopsy specimens.
• Common symptoms include fever, night sweats, and weight loss.
• Potential for systemic involvement, necessitating comprehensive staging.

ICD-10 Code C81.27 for Mixed cellularity Hodgkin lymphoma, spleen – SOAP Notes & Clinical Use

ICD-10 Code C81.27 is integral in SOAP notes for documenting the patient's symptoms, assessment findings, and treatment plans. It aids in ensuring accurate coding for both acute and chronic care settings, facilitating appropriate reimbursement and continuity of care.

What Does ICD-10 Code C81.27 for Mixed cellularity Hodgkin lymphoma, spleen Mean in SOAP Notes?

In SOAP notes, ICD-10 Code C81.27 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of Mixed cellularity Hodgkin lymphoma, spleen. This code supports continuity of care, justifies billing, and meets EHR documentation standards.

Treatment Options for ICD-10 Code C81.27 – Mixed cellularity Hodgkin lymphoma, spleen

Management of Mixed cellularity Hodgkin lymphoma, spleen often necessitates hospitalization for treatment initiation and monitoring.

Antibiotic Therapy:

• Not applicable as this is not an infectious condition.

Supportive Care:

• Chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine).
• Radiation therapy may be indicated in localized disease.
• Supportive measures for managing symptoms like pain and fatigue.

Infection Control:

• Standard precautions to prevent infection during chemotherapy.
• Monitoring for febrile neutropenia and prompt intervention as needed.

How to Document Symptoms of Mixed cellularity Hodgkin lymphoma, spleen (ICD-10 C81.27) in SOAP Notes

Subjective:

• Patient reports persistent fatigue and unexplained weight loss.
• Complaints of night sweats and intermittent fever.
• History of splenomegaly noted during previous evaluations.

Objective:

• Physical examination reveals splenomegaly.
• Laboratory tests show elevated lactate dehydrogenase (LDH).
• Biopsy confirms presence of Reed-Sternberg cells.

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Mixed cellularity Hodgkin lymphoma, spleen (ICD-10 Code C81.27)

Assessment:

• Diagnosis: Mixed cellularity Hodgkin lymphoma, spleen, Stage II.
• ICD-10 Code: C81.27.
• Contributing factors include age and gender predisposition.

Plan:

• Initiate chemotherapy with ABVD regimen.
• Schedule follow-up imaging to assess treatment response.
• Educate patient on potential side effects and symptom management.

Treatment & Plan Section for ICD-10 Code C81.27 – Mixed cellularity Hodgkin lymphoma, spleen

• First-line treatment includes combination chemotherapy (e.g., ABVD).
• Non-pharmacologic strategies include nutritional support and counseling.
• Monitoring through regular follow-up appointments and imaging studies.
• Patient education on recognizing symptoms of infection or treatment side effects.

Using ICD-10 Code C81.27 for Mixed cellularity Hodgkin lymphoma, spleen in Billing & SOAP Note Compliance

• Select appropriate ICD-10 codes based on clinical findings and treatment plans.
• Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
• Ensure treatment plans align with clinical guidelines to support justified billing.
• Use CPT codes that correspond to the services provided for accurate reimbursement.

Related ICD-10 Codes Often Used with Mixed cellularity Hodgkin lymphoma, spleen

• C81.20 – Hodgkin lymphoma, lymph nodes of head, face, and neck
• C81.30 – Hodgkin lymphoma, lymph nodes of axilla and upper limb
• C81.40 – Hodgkin lymphoma, lymph nodes of mediastinum

ICD-10 Code C81.27 in Medical Billing and Insurance for Mixed cellularity Hodgkin lymphoma, spleen

ICD-10 Code C81.27 is crucial for accurate billing in hospital, ER, or infectious disease care settings.

Billing Notes:

• Ensure documentation includes detailed clinical findings and treatment plans.
• Use the code in settings where the diagnosis is confirmed and treatment initiated.
• Highlight key chart elements such as biopsy results and treatment response.

Common CPT Pairings: